JAK inhibitor tofacitinib for treating rheumatoid arthritis: From basic to clinical

Modern Rheumatology

Volumn 23, Issue 3, 2013, Pages 415-424

  Tanaka, Yoshiya ^a   Yamaoka, Kunihiro ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Inflammation; JAK; Kinase; Rheumatoid arthritis; Treatment

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ERYTHROPOIETIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE INHIBITOR; METHOTREXATE; PLACEBO; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR;

AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CONNECTIVE TISSUE DISEASE; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; GASTROINTESTINAL DISEASE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HERPES ZOSTER; HUMAN; HYPERLIPIDEMIA; IN VITRO STUDY; INFECTION; INFECTION RATE; LUNG TUBERCULOSIS; MONOTHERAPY; MUSCULOSKELETAL DISEASE; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMOCYSTIS; PNEUMONIA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PULMONARY CRYPTOCOCCOSIS; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; TH17 CELL; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; JANUS KINASE 3; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; TREATMENT OUTCOME;

EID: 84877767875     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-012-0799-2     Document Type: Review

References (45)

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376:1094-108.
2. Smolen JS, Aletaha D, Bijlsma JWJ, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-7.
3. Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis. 2010;69:976-86.
4. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-6.
5. D'Aura Swanson C, Paniagua RT, Lindstrom TM, Robinson WH. Tyrosine kinases as targets for the treatment of rheumatoid arthritis. Nat Rev Rheumatol. 2009;5:317-24.
6. Johnston JA, Kawamura M, Kirken RA, et al. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature. 1994;370:151-3.
7. Yamaoka K, Saharinen P, Pesu M, et al. The Janus kinases (Jaks). Genome Biol. 2004;5:253-8.
8. Yamaoka K, Min B, Zhou YJ, et al. Jak3 negatively regulates dendritic-cell cytokine production and survival. Blood. 2005;106:3227-33.
9. Russell SM, Tayebi N, Nakajima H, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science. 1995;270:797-800.
10. Macchi P, Villa A, Giliani S, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature. 1995;377:65-8.
11. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228:273-87.
12. Kurzer JH, Argetsinger LS, Zhou YJ, et al. Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-B beta. Mol Cell Biol. 2004;24:4557-70.
13. Cheng H, Ross JA, Frost JA, Kirken RA. Phosphorylation of human Jak3 at tyrosines 904 and 939 positively regulates its activity. Mol Cell Biol. 2008;28:2271-82.
14. Funakoshi-Tago M, Tago K, Kasahara T, et al. Negative regulation of Jak2 by its auto-phosphorylation at tyrosine 913 via the Epo signaling pathway. Cell Signal. 2008;20:1995-2001.
15. Walker JG, Ahern MJ, Coleman M, et al. Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis. 2006;65:149-56.
16. Pesu M, Laurence A, Kishore N, et al. Therapeutic targeting of Janus kinases. Immunol Rev. 2008;223:132-42.
17. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003;302:875-8.
18. Chrencik JE, Patny A, Leung IK, et al. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. J Mol Biol. 2010;400:413-33.
19. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26:127-32.
20. Flanagan ME, Blumenkopf TA, Brissette WH, et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem. 2010;53:8468-84.
21. + T-Cell-mediated acute graft-versus-host disease by inhibiting the interferon-gamma pathway. Transplantation. 2010;90:825-35.
22. Paniagua R, Si MS, Flores MG, et al. Effects of Jak3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts. Transplantation. 2005;80:1283-92.
23. Milici AJ, Kudlacz EM, Audoly L, et al. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther. 2008;10:R14.
24. Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the Jak1/Jak3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm. 2010;7:41.
25. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186:4234-43.
26. + T cells. Arthritis Rheum. 2012;64:1790-8.
27. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dose levels of CP-690,550 versus placebo. Arthritis Rheum. 2009;60:1895-905.
28. Coombs JH, Bloom BJ, Breedveld FC, et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (Jak) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2010;69:413-6.
29. Tanaka Y, Suzuki M, Nakamura H, et al. Phase 2 study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and inadequate response to methotrexate. Arthritis Care Res. 2011;63:1150-8.
30. Tanaka Y, Takeuchi T, Yamanaka H, et al. Tofacitinib (CP-690,550), An oral Janus kinase inhibitor, as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week phase 2b study [abstract]. Arthritis Rheum 2011; 63(Suppl):#2192.
31. Takeuchi T, Tanaka Y, Yamanaka H, et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, as monotherapy in patients with active rheumatoid arthritis: a comparison between Japanese and global populations over 12 weeks of dosing in phase 2b studies [abstract]. Arthritis Rheum 2011;63(Suppl):#1213.
32. Fleischmann RM, Krishnaswami S, Gruben D, et al. Improvements in disease activity score by baseline status: pooled analysis of five phase 3 studies with tofacitinib (CP-690,550) in patients with active rheumatoid arthritis [abstract]. Ann Rheum Dis 2012;71(Suppl3):207.
33. van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis: a 24-month phase 3 study [abstract]. Arthritis Rheum 2011;63(Suppl):#2592.
34. Fleischmann RM, Kremer JM, Cush JJ, et al. ORAL Solo Investigators. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495-507.
35. Kremer J, Li Z-G, Hall S, et al. Tofacitinib (CP-690,550), an oral Jak inhibitor, in combination with traditional DMARDs: phase 3 study in patients with active rheumatoid arthritis with inadequate response to DMARDs [abstract]. Ann Rheum Dis 2011;70(Suppl3):170.
36. van Vollenhoven RF, Fleischmann RM, Cohen SB, et al. ORAL Standard Investigators. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508-19.
37. Wollenhaupt J, Silverfield JC, Lee EB, et al. Background/purpose: tofacitinib (CP-690,550), an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: open-label, long-term extension studies up to 36 months [abstract]. Arthritis Rheum 2011;63(Suppl):#407.
38. Kremer JM, Cohen S, Wilkinson BE, et al. A phase 2b dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate alone. Arthritis Rheum. 2012;64:970-81.
39. Burmester G, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550), an oral janus kinase inhibitor, in combination with methotrexate, in patients with active rheumatoid arthritis with an inadequate response to tumor necrosis factor-inhibitors: a 6-month phase 3 study [abstract]. Arthritis Rheum 2011;63(Suppl):#718.
40. Fleischmann R, Cutolo M, Genovese MC, et al. Phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to DMARDs. Arthritis Rheum. 2012;64:617-29.
41. Yamanaka H, Tanaka T, Takeuchi T, et al. Tofacitinib (CP-690,550), an oral janus kinase inhibitor, as monotherapy or with background methotrexate in Japanese patients with rheumatoid arthritis: a phase 2/3 long-term extension study [abstract]. Arthritis Rheum 2011;63(Suppl):#1215.
42. Cohen S, Radominski SC, Asavatanabodee P, et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor: analysis of infections and all-cause mortality across phase 3 and long-term extension studies in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2011;63(Suppl):#409.
43. Sonomoto K, Yamaoka K, Kubo S, et al. Relevance of involvement of tofacitinib in T cell subsets to clinical courses in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2011;63(Suppl):#2230.
44. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19:12-9.
45. Fleischmann R, Spencer-Green GT, Fan F, et al. Dose ranging study of VX-509, an oral selective JAK3 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2011;63(Suppl):#L3.